Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Stock analysts at Leerink Swann dropped their FY2017 earnings per share (EPS) estimates for shares of Celldex Therapeutics in a research note issued on Tuesday. Leerink Swann analyst S. Fernandez now expects that the biopharmaceutical company will post earnings per share of ($0.98) for the year, down from their previous forecast of ($0.97). Leerink Swann also issued estimates for Celldex Therapeutics’ Q4 2017 earnings at ($0.24) EPS and FY2018 earnings at ($0.94) EPS.

Other equities research analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Tuesday, July 11th. Cowen and Company reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research note on Tuesday, June 6th. HC Wainwright set a $10.00 price target on shares of Celldex Therapeutics and gave the stock a “buy” rating in a research note on Wednesday. ValuEngine downgraded shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 3rd. Finally, BidaskClub downgraded shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. Celldex Therapeutics currently has a consensus rating of “Hold” and an average price target of $7.32.

COPYRIGHT VIOLATION WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/fy2017-eps-estimates-for-celldex-therapeutics-inc-cldx-reduced-by-analyst/1472124.html.

Shares of Celldex Therapeutics (CLDX) traded up 2.47% during midday trading on Friday, hitting $2.49. 395,487 shares of the stock were exchanged. The firm has a 50 day moving average of $2.47 and a 200-day moving average of $3.01. Celldex Therapeutics has a 12 month low of $2.20 and a 12 month high of $5.02. The stock’s market cap is $311.51 million.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.05. The firm had revenue of $3.83 million for the quarter, compared to analyst estimates of $1.21 million. Celldex Therapeutics had a negative net margin of 1,318.94% and a negative return on equity of 51.87%. The company’s revenue for the quarter was up 175.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.32) EPS.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Parametric Portfolio Associates LLC increased its position in Celldex Therapeutics by 2.2% in the first quarter. Parametric Portfolio Associates LLC now owns 65,884 shares of the biopharmaceutical company’s stock valued at $238,000 after buying an additional 1,409 shares in the last quarter. Teachers Advisors LLC increased its position in Celldex Therapeutics by 0.9% in the fourth quarter. Teachers Advisors LLC now owns 167,582 shares of the biopharmaceutical company’s stock valued at $593,000 after buying an additional 1,433 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Celldex Therapeutics by 0.9% in the first quarter. Goldman Sachs Group Inc. now owns 280,425 shares of the biopharmaceutical company’s stock valued at $1,012,000 after buying an additional 2,453 shares in the last quarter. Nationwide Fund Advisors increased its position in Celldex Therapeutics by 3.5% in the second quarter. Nationwide Fund Advisors now owns 111,757 shares of the biopharmaceutical company’s stock valued at $276,000 after buying an additional 3,742 shares in the last quarter. Finally, American International Group Inc. increased its position in Celldex Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 58,838 shares of the biopharmaceutical company’s stock valued at $212,000 after buying an additional 3,880 shares in the last quarter. 65.83% of the stock is currently owned by institutional investors.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Earnings History and Estimates for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.